Not included studies supported by NBCG but without NBCG involvement
| Study | NBCG-numbering | Reference/ comment | |
| 1 | Svenocam1 | Weekly Adriamycin versus VAC in dvanced breast cancer. A randomized trial. | 1 |
| 2 | Svenocam2 | Weekly Adriamycin vs. 4-epidoxorubicin every second week in dvanced breast cancer. A randomized trial. | 2 |
| 3 | Svenocam3 | Megestrol acetate versus aminoglutethimide for metastatic breast cancer. | 3 |
| 4 | NBCG1 | Adjuvant tamoxifen for pre- and postmenopausal women with estrogen receptor positive, node positive breast cancer: a randomized study. | 4, 8 |
| 5 | NBCG2 | Adjuvant endocrine treatment (goserelin vs tamoxifen) in pre-menopausal patients with operable node positive stage II breast cancer. A prospective randomized national multicenter study. | 5, 8 |
| 6 | NBCG3 | Cyclical use of tamoxifen and high-dose medroxyprogesterone acetate in advanced estrogen receptor positive breast cancer. | 6-8 |
| 7 | Droloxifen study 1: Influence of treatment with the anti-oestrogen 3-hydroxytamoxifen (droloxifene) on plasma sex hormone levels in postmenopausal patients with breast cancer | 36 | |
| 8 | – | Droloxifen study 2: Influence of droloxifene on metastatic breast cancer as first-line endocrine treatment. | 37 |
| 9 | NBCG4 | Protocol for treatment and FU of in situ carcinomas | Premature closure (no results) |
| 10 | SBG9401 | Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. | 27-29 |
| 11 | SBG9404 | Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure | 30 |
| 12 | NBCG5 | Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. | 9 |
| 13 | Exe027 | A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. | 32-35 |
| 14 | NBCG6/ NeoTax | Evaluation of epi-adriamycin versus paclitaxel for primary medical treatment (“neo-adjuvant chemotherapy” in patients with locally advanced (stage III, T3/4 and/or N2) non-inflammatory breast cancer with or without limited distant metastases; phase II study | 10-14, analyses ongoing |
| 15 | NBCG7/ Exe031 | Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. | 15-16 |
| 16 | HERA | Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. | 26 |
| HABITS | Hormone replacement therapy in breast cancer survivors – is it safe. | 31 | |
| 17 | NBCG8 | Evaluation of clinical effects of and predictive factors to docetaxel and trastuzumab in sequence followed by combination as first line treatment in patients with HER2-positive breast cancers. | Closed before study was started |
| 18 | NBCG9/ SATT | Secondary Adjuvant (rescue) Treatment with docetaxel (Taxotere) and detection of isolated tumor cells in bone marrow as a surrogate marker for effect – in node positive and high risk node negative breast cancer after standard adjuvant epirubicin-containing treatment (SATT) | 17-19, analyses ongoing |
| 19 | NBCG10 | Weekly Paclitaxel plus Capecitabine versus Docetaxel Every 3 Weeks plus Capecitabine in Metastatic Breast Cancer. | 20 |
| 20 | NBCG11/ ABCSG21 | A randomized phase II study comparing anastrozole and fulvestrant to anastrozole for adjuvant treatment of postmenopausal patients with early breast cancer and disseminated tumour cells in bone marrow | Premature closure (no results) |
| 21 | NBCG12/ ALTTO | Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation study. A randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients | 21,22 |
| 22 | NBCG13/ NeoALTTO | NeoALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) study. A randomised, multicentre, open-label, phase III study of neoadjuvant lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2/ErbB2 positive primary breast cancer | 23,24 |
| 23 | NBCG14/ EBBA2 | Energy Balance and Breast Cancer Aspects (EBBA2) | 25 Closed for inclusion, follow up and analyses ongoing |
| 24 | NBCG15/ PETREMAC | PErsonalized TREatment of high-risk MAmmary Cancer – the PETREMAC Trial | Ongoing recruitment |
| 25 | NBCG16/ IBCSG 48-14 | Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer | Ongoing recruitment |
| 26 | NBCG17/ ALICE | Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer | Ongoing recruitment |
| 27 | NBCG18/ ICON | A randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with luminal B breast cancer. | Ongoing recruitment |
| 28 | NBCG19/ EMIT1 | Establishment of Molecular profiling for Individual clinical routine Treatment decision in Early Breast Cancer | Ongoing recruitment |
| 29 | NBCG20/ OPTIMA | Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis (OPTIMA)/ EMITEBC-2 | Ongoing recruitment |
| 30 | NBCG21/ NATURAL (DBCG) | Partial Breast Versus no Irradiation for Women >=60 Years Operated With Breast Conservation for Early Breast Cancer: a Clinically Controlled Randomized Phase III Trial | Ongoing recruitment |
Studies being planned
| 1 | PETREMAC2 | PErsonalized TREatment of high-risk MAmmary Cancer – the PETREMAC 2 Trial | |
| 2 | INDAX | Individualized axillary treatment of initially biopsy-proven node-positive breast cancer after neoadjuvant chemotherapy: the EUBREAST-2 INDAX Trial |
Reference list for NBCG studies (mainly investigator-initiated)(according to study)
Pre NBCG numbered studies (SVENOCAM)
1. Gundersen S, Kvinnsland S, Klepp O, Kvaløy S, Lund E, Høst H. Weekly adriamycin versus VAC in advanced breast cancer. A randomized trial. Eur J Cancer Clin Oncol. 1986 Dec;22(12):1431-4. PubMed PMID: 3595668.
2. Lundgren S, Gundersen S, Klepp R, Lønning PE, Lund E, Kvinnsland S. Megestrol acetate versus aminoglutethimide for metastatic breast cancer. Breast Cancer Res Treat. 1989 Nov;14(2):201-6. PubMed PMID: 2690972.
3. Gundersen S, Kvinnsland S, Klepp O, Lund E, Høst H. Weekly Adriamycin vs. 4-epidoxorubicin every second week in advanced breast cancer. A randomized trial. The Norwegian Breast Cancer Group. Eur J Cancer. 1990 Jan;26(1):45-8. PubMed PMID: 2138477.
NBCG1
4. Gundersen S, Hannisdal E, Søreide JA, Skarstein A, Varhaug JE. Adjuvant tamoxifen for pre- and postmenopausal women with estrogen receptor positive, node positive breast cancer: a randomized study. Breast Cancer Res Treat. 1995;36(1):49-53. PubMed PMID: 7579506.
NBCG2
5. Söreide JA, Varhaug JE, Fjösne HE, Erikstein B, Jacobsen AB, Skovlund E, Kvinnsland S. Adjuvant endocrine treatment (goserelin vs tamoxifen) in pre-menopausal patients with operable node positive stage II breast cancer. A prospective randomized national multicenter study. Eur J Surg Oncol. 2002 Aug;28(5):505-10. PubMed PMID: 12217302.
NBCG3
6. Gundersen S, Kvinnsland S, Lundgren S, Klepp O, Lund E, Børmer O, Høst H. Cyclical use of tamoxifen and high-dose medroxyprogesterone acetate in advanced estrogen receptor positive breast cancer. Breast Cancer Res Treat. 1990 Nov;17(1):45-50. PubMed PMID: 2151369.
7. Fjøsne HE, Jacobsen AB, Lundgren S; Norwegian Breast Cancer Group (NBCG). Adjuvant cyclic Tamoxifen and Megestrol acetate treatment in postmenopausal breast cancer patients–longterm follow-up. Eur J Surg Oncol. 2008 Jan;34(1):6-12. Epub 2007 Sep 18. PubMed PMID: 17881183.
NBCG 1-3 (pooled study)
8. Fjösne HE, Søreide JA, Kåresen R, Lønning PE, Jacobsen AB, Lundgren S; NORWEGIAN BREAST CANCER GROUP (NBCG). Hospital volume and prognosis among Norwegian breast cancer patients enrolled in adjuvant trials. Acta Oncol. 2011 Oct;50(7):1068-74. doi: 0.3109/0284186X.2011.585998. Epub 2011 Jul 11. PubMed PMID: 21745131.
NBCG4 (DCIS protocol) (Premature closure; no results)
NBCG5 (bisphosphonate adjuvant)
9. Powles T, Paterson S, Kanis JA, McCloskey E, Ashley S, Tidy A, Rosenqvist K, Smith I, Ottestad L, Legault S, Pajunen M, Nevantaus A, Männistö E, Suovuori A, Atula S, Nevalainen J, Pylkkänen L. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol. 2002 Aug 1;20(15):3219-24. PubMed PMID: 12149294.
NBCG6
10. Knappskog S, Berge EO, Chrisanthar R, Geisler S, Staalesen V, Leirvaag B, Yndestad S, de Faveri E, Karlsen BO, Wedge DC, Akslen LA, Lilleng PK, Løkkevik E, Lundgren S, Østenstad B, Risberg T, Mjaaland I, Aas T, Lønning PE. Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo. Mol Oncol. 2015 Oct;9(8):1553-64. doi: 10.1016/j.molonc.2015.04.008. Epub 2015 May 8. PubMed PMID: 26004085; PubMed Central PMCID: PMC5528784.
11. Knappskog S, Gansmo LB, Romundstad P, Bjørnslett M, Trovik J, Sommerfelt-Pettersen J, Løkkevik E; Norwegian Breast Cancer Group trial NBCG VI, Tollenaar RA, Seynaeve C, Devilee P, Salvesen HB, Dørum A, Hveem K, Vatten L, Lønning PE. MDM2 promoter SNP344T>A (rs1196333) status does not affect cancer risk. PLoS One. 2012;7(4):e36263. doi: 10.1371/journal.pone.0036263. Epub 2012 Apr 30. PubMed PMID: 22558411; PubMed Central PMCID: PMC3340411.
12. Chrisanthar R, Knappskog S, Løkkevik E, Anker G, Østenstad B, Lundgren S, Berge EO, Risberg T, Mjaaland I, Maehle L, Engebretsen LF, Lillehaug JR, Lønning PE. CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer. PLoS One. 2008 Aug 26;3(8):e3062. doi: 10.1371/journal.pone.0003062. PubMed PMID: 18725978; PubMed Central PMCID: PMC2518116.
13. Chrisanthar R, Knappskog S, Løkkevik E, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Skjønsberg G, Aas T, Schlichting E, Fjösne HE, Nysted A, Lillehaug JR, Lønning PE. Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel. PLoS One. 2011 Apr 27;6(4):e19249. doi: 10.1371/journal.pone.0019249. PubMed PMID: 21556366; PubMed Central PMCID: PMC3083424.
14. Mathiesen RR, Borgen E, Renolen A, Løkkevik E, Nesland JM, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Kvalheim G, Lønning PE, Naume B. Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival. Breast Cancer Res. 2012 Aug 14;14(4):R117. doi: 10.1186/bcr3242. PubMed PMID: 22889108; PubMed Central PMCID: PMC3680942.
NBCG7
15. Lønning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI, Schlichting E, Lien EA, Ofjord ES, Paolini J, Polli A, Massimini G. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol. 2005 Aug 1;23(22):5126-37. Epub 2005 Jun 27. PubMed PMID: 15983390.
16. Geisler J, Lønning PE, Krag LE, Løkkevik E, Risberg T, Hagen AI, Schlichting E, Lien EA, Ofjord ES, Eide GE, Polli A, di Salle E, Paolini J. Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study. Eur J Cancer. 2006 Nov;42(17):2968-75. Epub 2006 Sep 11. PubMed PMID: 16963261.
NBCG8 (closed before the study was started)
NBCG9
17. Synnestvedt M, Borgen E, Wist E, Wiedswang G, Weyde K, Risberg T, Kersten C, Mjaaland I, Vindi L, Schirmer C, Nesland JM, Naume B. Disseminated tumor cells as selection marker and monitoring tool for secondary adjuvant treatment in early breast cancer. Descriptive results from an intervention study. BMC Cancer. 2012 Dec 22;12:616. doi: 10.1186/1471-2407-12-616. PubMed PMID: 23259667; PubMed Central PMCID: PMC3576235.
18. Gilje B, Nordgård O, Tjensvoll K, Borgen E, Synnestvedt M, Smaaland R, Naume B. Comparison of molecular and immunocytochemical methods for detection of disseminated tumor cells in bone marrow from early breast cancer patients. BMC Cancer. 2014 Jul 15;14:514. doi: 10.1186/1471-2407-14-514. PubMed PMID: 25023626; PubMed Central PMCID: PMC4223548.
19. Naume B, Synnestvedt M, Falk RS, Wiedswang G, Weyde K, Risberg T, Kersten C, Mjaaland I, Vindi L, Sommer HH, Sætersdal AB, Rypdal MC, Bendigtsen Schirmer C, Wist EA, Borgen E. Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-guided secondary adjuvant treatment with docetaxel in early breast cancer. J Clin Oncol. 2014 Dec 1;32(34):3848-57. doi: 10.1200/JCO.2014.56.9327. Epub 2014 Nov 3. PubMed PMID: 25366688.
NBCG10
20. Wist EA, Mjaaland I, Løkkevik E, Sommer HH. Weekly Paclitaxel plus Capecitabine versus Docetaxel Every 3 Weeks plus Capecitabine in Metastatic Breast Cancer. J Oncol. 2012;2012:862921. doi: 10.1155/2012/862921. Epub 2012 Jan 15. PubMed PMID: 22291703; PubMed Central PMCID: PMC3265117.
NBCG11 (ABCSG21) (Premature closure; no results)
NBCG12
21. Piccart-Gebhart M, Holmes E, Baselga J, de Azambuja E, Dueck AC, Viale G, Zujewski JA, Goldhirsch A, Armour A, Pritchard KI, McCullough AE, Dolci S, McFadden E, Holmes AP, Tonghua L, Eidtmann H, Dinh P, Di Cosimo S, Harbeck N, Tjulandin S, Im YH, Huang CS, Diéras V, Hillman DW, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Gomez H, Suter T, Gelber RD, Perez EA. Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. J Clin Oncol. 2016 Apr 1;34(10):1034-42. doi: 10.1200/JCO.2015.62.1797. Epub 2015 Nov 23. PubMed PMID: 26598744; PubMed Central PMCID: PMC4872016.
22. Gingras I, Holmes E, De Azambuja E, Nguyen DH, Izquierdo M, Anne Zujewski J, Inbar M, Naume B, Tomasello G, Gralow JR, Wolff AC, Harris L, Gnant M, Moreno-Aspitia A, Piccart MJ, Azim HA Jr. Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial. J Natl Cancer Inst. 2017 Aug 1;109(8). doi: 10.1093/jnci/djw331. PubMed PMID: 28376188.
NBCG13
23. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horváth Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M; NeoALTTO Study Team. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012 Feb 18;379(9816):633-40. doi: 10.1016/S0140-6736(11)61847-3. Epub 2012 Jan 17. Erratum in: Lancet. 2012 Feb 18;379(9816):616. Dosage error in published abstract; MEDLINE/PubMed abstract corrected. PubMed PMID: 22257673; PubMed Central PMCID: PMC5705192.
24. Di Cosimo S, Campbell C, Azim HA Jr, Galli G, Bregni G, Curigliano G, Criscitiello C, Izquierdo M, de la Pena L, Fumagalli D, Fein L, Vinholes J, Ng WMJ, Colleoni M, Ferro A, Naume BJ, Patel A, Huober J, Piccart-Gebhart MJ, Baselga J, de Azambuja E. The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO. Eur J Cancer. 2018 Jan;89:42-48. doi: 10.1016/j.ejca.2017.10.036. Epub 2017 Dec 8. PubMed PMID: 29227816; PubMed Central PMCID: PMC5777154.
NBCG14/EBBA2
25. Vaysse C, Lømo J, Garred Ø, Fjeldheim F, Lofteroed T, Schlichting E, McTiernan A, Frydenberg H, Husøy A, Lundgren S, Fagerland MW, Richardsen E, Wist EA, Muller C, Thune I. Erratum: Inflammation of mammary adipose tissue occurs in overweight and obese patients exhibiting early-stage breast cancer. NPJ Breast Cancer. 2017 Sep 5;3:35. doi: 10.1038/s41523-017-0030-x. eCollection 2017. PubMed PMID: 28884144; PubMed Central PMCID: PMC5585409. (Phila). 2015 Jun;8(6):535-44. doi: 10.1158/1940-6207.CAPR-14-0267. Epub 2015 Mar 24.
HERA
26. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sánchez Rovira P, Piccart-Gebhart MJ; HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007 Jan 6;369(9555):29-36. PubMed PMID: 17208639.
SBG9401
27. Brandberg Y, Michelson H, Nilsson B, Bolund C, Erikstein B, Hietanen P, Kaasa S, Nilsson J, Wiklund T, Wilking N, Bergh J; Scandinavian Breast Group Study 9401. Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow-supported high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin or tailored therapy with Fluorouracil, epirubicin, and cyclophosphamide: Scandinavian Breast Group Study 9401. J Clin Oncol. 2003 Oct 1;21(19):3659-64. PubMed PMID: 14512398.
28. Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmström P, Kellokumpu-Lehtinen P, Bengtsson NO, Söderlund G, Anker G, Wist E, Ottosson S, Salminen E, Ljungman P, Holte H, Nilsson J, Blomqvist C, Wilking N. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. Lancet. 2000 Oct 21;356(9239):1384-91.
29. Drageset V, Nesland JM, Erikstein B, Skovlund E, Sommer H, Anker G, Wist E, Lundgren S, Bergh J, Kvalheim G. Monitoring of disseminated tumor cells in bone marrow in high-risk breast cancer patients treated with high-dose chemotherapy. Int J Cancer. 2006 Jun 1;118(11):2877-81. PubMed PMID: 16381016
SBG9404
30. Sjöström J, Blomqvist C, Mouridsen H, Pluzanska A, Ottosson-Lönn S, Bengtsson NO, Ostenstad B, Mjaaland I, Palm-Sjövall M, Wist E, Valvere V, Anderson H, Bergh J. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer. 1999 Aug;35(8):1194-201. PubMed PMID: 10615229.
HABITS
31. Holmberg L(1), Iversen OE, Rudenstam CM, Hammar M, Kumpulainen E, Jaskiewicz J, Jassem J, Dobaczewska D, Fjosne HE, Peralta O, Arriagada R, Holmqvist M, Maenpaa J; HABITS Study Group. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst. 2008 Apr 2;100(7):475-82. doi: 10.1093/jnci/djn058. Epub 2008 Mar 25.
Exemestane adjuvant 027
32.Morden JP, Alvarez I, Bertelli G, Coates AS, Coleman R, Fallowfield L, Jassem J, Jones S, Kilburn L, Lønning PE, Ortmann O, Snowdon C, van de Velde C, Andersen J, Del Mastro L, Dodwell D, Holmberg S, Nicholas H, Paridaens R, Bliss JM, Coombes RC. Long-Term Follow-Up of the Intergroup Exemestane Study. J Clin Oncol. 2017 Aug 1;35(22):2507-2514. doi: 10.1200/JCO.2016.70.5640. Epub 2017 May 3. PubMed PMID: 28467729.
33. Bliss JM, Kilburn LS, Coleman RE, Forbes JF, Coates AS, Jones SE, Jassem J, Delozier T, Andersen J, Paridaens R, van de Velde CJ, Lønning PE, Morden J, Reise J, Cisar L, Menschik T, Coombes RC. Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study. J Clin Oncol. 2012 Mar 1;30(7):709-17. doi: 10.1200/JCO.2010.33.7899. Epub 2011 Oct 31. PubMed PMID: 22042946.
34. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM, van de Velde C; Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004 Mar 11;350(11):1081-92. Erratum in: N Engl J Med. 2004 Dec 2;351(23):2461. N Engl J Med. 2006 Oct 19;355(16):1746. van de Velde, Cornelius. PubMed PMID: 15014181.
35. Cheang MCU, Bliss JM, Viale G, Speirs V, Palmieri C, Shaaban A, Lønning PE, Morden J, Porta N, Jassem J, van De Velde CJ, Rasmussen BB, Verhoeven D, Bartlett JMS, Coombes RC; PathIES Sub-Committee. Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES. Breast Cancer Res Treat. 2017 Nov 24. doi: 10.1007/s10549-017-4543-7. [Epub ahead of print] PubMed PMID: 29177605.
Droloxifen study 1
36. Geisler J, Haarstad H, Gundersen S, Raabe N, Kvinnsland S, Lønning PE. Influence of treatment with the anti-oestrogen 3-hydroxytamoxifen (droloxifene) on plasma sex hormone levels in postmenopausal patients with breast cancer. J Endocrinol. 1995 Aug;146(2):359-63. PubMed PMID: 7561649.
Droloxifen study 2
37. Haarstad H, Lønning PE, Gundersen S, Wist E, Raabe N, Kvinnsland S. Influence of droloxifene on metastatic breast cancer as first-line endocrine treatment. Acta Oncol. 1998;37(4):365-8. PubMed PMID: 9743458.
Other relevant studies
38. Francolini G, Thomsen MS, Yates ES, Kirkove C, Jensen I, Blix ES, Kamby C, Nielsen MH, Krause M, Berg M, Mjaaland I, Schreiber A, Kasti UM, Boye K, Offersen BV. Quality assessment of delineation and dose planning of early breast cancer patients included in the randomized Skagen Trial 1. Radiother Oncol. 2017 May;123(2):282-287. doi: 10.1016/j.radonc.2017.03.011. Epub 2017 Mar 25. PubMed PMID: 28351523.
39. Dumeaux V, Fjukstad B, Fjosne HE, Frantzen JO, Holmen MM, Rodegerdts E, Schlichting E, Børresen-Dale AL, Bongo LA, Lund E, Hallett M. Interactions between the tumor and the blood systemic response of breast cancer patients. PLoS Comput Biol. 2017 Sep 28;13(9):e1005680. doi: 10.1371/journal.pcbi.1005680. eCollection 2017 Sep. PubMed PMID: 28957325; PubMed Central PMCID: PMC5619688.
40. Dumeaux V, Ursini-Siegel J, Flatberg A, Fjosne HE, Frantzen JO, Holmen MM, Rodegerdts E, Schlichting E, Lund E. Peripheral blood cells inform on the presence of breast cancer: a population-based case-control study. Int J Cancer. 2015 Feb 1;136(3):656-67. doi: 10.1002/ijc.29030. Epub 2014 Jun 25. PubMed PMID: 24931809; PubMed Central PMCID: PMC4278533.
41. Norum J, Olsen JA, Wist EA, Lønning PE. Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis. Acta Oncol. 2007;46(2):153-64. PubMed PMID: 17453363. 0
42. Eldesoky AR, Yates ES, Nyeng TB, Thomsen MS, Nielsen HM, Poortmans P, Kirkove C, Krause M, Kamby C, Mjaaland I, Blix ES, Jensen I, Berg M, Lorenzen EL, Taheri-Kadkhoda Z, Offersen BV. Internal and external validation of an ESTRO delineation guideline – dependent automated segmentation tool for loco-regional radiation therapy of early breast cancer. Radiother Oncol. 2016 Dec;121(3):424-430. doi: 10.1016/j.radonc.2016.09.005. PubMed PMID: 27697296.
NBCG 